Hypoglycaemic and anti-hyperglycaemic activity of Tabernanthe iboga aqueous extract in fructose-fed streptozotocin type 2 diabetic rats

Abstract

Root bark preparations of the Gabonese plant Tabernanthe iboga (T. iboga) has long been used in traditional medicine in Central and West African regions for the management of type 2 diabetes (T2D). This study is the first investigation of in vivo hypoglycaemic activity in healthy rats and anti-hyperglycaemic activity of T. iboga in a 10% fructose-fed (40 mg/kg (i.p.) streptozotocin (STZ) injected type 2 diabetic rat model.T. iboga at 50 to 200 mg/kg induced hypoglycaemia activity over 3 hours fasted glucose tolerance in healthy Wistar rats and anti-hyperglycaemic effects on non-fasted and fasted blood glucose in fructose-fed STZ T2D rats with no toxicity.Fructose-fed STZ T2D rats developed characteristic type 2 diabetic complications over 6 weeks exhibiting significantly elevated fasting and non-fasting blood glucose, polydipsia, reduced body weight gain and glucose and insulin tolerance compared with STZ alone and normal control rats. T. iboga (50 mg/kg and 200 mg/kg bw) administered p.o. once daily for 4 weeks significantly improved diabetic symptoms of polydipsia, reduced body weight, hyperglycaemia, glucose and insulin tolerance (as AUC) compared with fructose-fed STZ T2D rats. T. iboga aqueous extract (50 mg/kg and 200 mg/kg) also significantly reversed altered actions of marker enzymes of liver including alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase (AST), creatinine, HbA1c and elevated triglycerides in fructose-fed STZ type 2 diabetic rats. Our outcomes show that daily oral provision of T. iboga improves type 2 diabetes complications, superior to glibenclamide, in rat fructose-fed STZ model and offers the potential for safe clinical management of T2D in Gabon.

Modulatory Effect of Medicinal Plants and Their Active Constituents on ATP-Sensitive Potassium Channels (KATP) in Diabetes

“…Similarly, Bading-Taïka et al also showed that T. iboga aqueous extract (50 to 200 mg/kg p.o.) had a hypoglycemic impact on healthy rats [78]. This effect was delayed and only manifested after 3 h, which may be indicative of the intracellular action of the compound as previously demonstrated in isolated pancreatic β-cells by Souza et al [79].…”

“…This effect was delayed and only manifested after 3 h, which may be indicative of the intracellular action of the compound as previously demonstrated in isolated pancreatic β-cells by Souza et al [79]. Additionally, T. iboga aqueous extract showed antihyperglycemic effects on non-fasted and fasted blood glucose in fructose-fed STZ diabetic rats [78].…”

“…Tabernanthe iboga belongs to the Apocynaceae family and is widely grown in the tropical forest of Central Africa. Root bark preparations have long been used in traditional medicine in Central and West African regions for the management of type 2 diabetes [78]. Despite this, scientific evidence on the antidiabetic effects of T. iboga is very limited.…”

Statistical Bioinformatics to Uncover the Underlying Biological Mechanisms That Linked Smoking with Type 2 Diabetes Patients Using Transcritpomic and GWAS Analysis

“…Another represented that a higher casualty of T2D is connected with lower HDL cholesterol levels [ 17 , 18 ], and smoking cigarettes is also linked to lower HDL cholesterol levels [ 19 , 20 ]. In addition, increased (triglycerides) TG levels were found to be substantially linked to the development of T2D [ 21 , 22 ], whether smoking helps increases triglycerides [ 23 ].…”